RedC Biotech ltd.

4

up
more


About

RedC is developing a process to produce universal red blood cells for life saving transfusions. (Read more)

Location: Israel

Start Date: May 2015

Team members: 2 (Read more)

Info

Category: Startup

Industry: Impact

Raising: $4,000,000

Project Timeline

Dec 31, 2021

Establish scaleup lab

Dec 31, 2023

Preparing for clinical trials

Dec 31, 2025

Commercialization prep



Project Overview


                RedC is developing a process to produce universal red blood cells for life saving transfusions.

                RedC Biotech is developing an innovative process for the industrial production of universal red blood cells (RBCs) to be used for lifesaving blood transfusions and advanced therapies in a massive scale and at low cost, addressing the need of a $20B global market and eliminating the need for blood donations.
            

Fund usage

The use of the funds will be for establishing our own lab, hiring 4 scientists and engineers and conducting research and development for 2 years.  

Technical description

Universal red blood cells for life saving transfusions and advanced therapies. Safe and high quality universal red blood cell transfusions, pathogen free, cost effective and high availability without the need for volunteer donors. In advanced therapies, small amounts of universal red blood cells are used to deliver therapeutic agents to patients, leveraging the unique characteristics of universal red blood cells.
A patented breakthrough technology for single cell 3D suspension cultures for stem cell cultivation using chemically defined serum free growth media.
Universal, red blood cells (RBCs) one blood type for all patients, removing the need of matching blood types and crossmatching. High Quality RBCs, pathogen free, no undesired blood Components, 100% clean of foreign white blood cells, plasma components, antibodies, DNA etc. Remove the need of donors and volunteers. Cost effective, price to be competitive or equal to the current donated blood. Access and Availability, meet demand.  

Users & Customers summary

The direct customers are the hospitals, the patients are the end users. Red blood cells carry oxygen to the body tissues and blood transfusions are a cornerstone in the treatment of trauma, childbirth, surgery, and treatments for chronic anemia in cancer patients, Sickle Cell Anemia and Thalassemia sufferers.
Hospitals - 160,000 worldwide (WW). Blood donation agencies, like the Red Cross, Red Crescent, and other independent blood donation agencies - about 200 and 100 WW, respectively. Military organizations - about 200 WW. Disaster relief agencies - about 30 WW.  

About

RedC is developing a process to produce universal red blood cells for life saving transfusions. (Read more)

Location: Israel

Start Date: May 2015

Team members: 2 (Read more)

Info

Category: Startup

Industry: Impact

Tags: Biotechnology, Impact

Stage: Series A

Funding: $4,000,000




The Team

Founder & CEO

Ari Gargir

Co-founder & Directo

Motti Vaknin